Home-based BCG therapy for bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests giving BCG immunotherapy at home instead of in the clinic, to reduce the burden of travel and hospital visits. It may help patients with non-muscle invasive bladder cancer who need BCG treatment after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-muscle invasive bladder cancer and had surgery (TURBT) within the past 6 weeks.
- Your cancer is considered intermediate or high risk by your doctor.
- Your doctor has recommended BCG therapy, and you have not had BCG in the past year.
- You can have a medical visitor at home, have a private space without pets or small children, and can hold your urine for at least 2 hours.
- You live in the service area of the home health service and have reliable access to phone or video for check-ins.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether changing your position while receiving BCG treatment (a liquid medicine placed directly into the bladder) can help it work better. You will wear a fitness tracker for a few days to monitor activity.
This trial tests whether patients with early-stage bladder cancer can safely receive their usual bladder chemotherapy or immunotherapy at home instead of in the clinic. It aims to make treatment more convenient while keeping it effective.
This study is testing a way for people with early-stage bladder cancer to receive their BCG treatment at home, with extra support. It aims to see if doing treatment at home is safe and helpful for patients.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests a personalized approach to using BCG immunotherapy for high-risk non-muscle-invasive bladder cancer. It aims to improve treatment response by tailoring the therapy based on your immune system.
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
Hear when a new Non-Muscle Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.